Hypermethylated Genes of MicroRNA in Ovarian Carcinoma: Metastasis Prediction Marker Systems


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

We identified a group of miRNA genes whose methylation is associated with ovarian cancer metastasis. Based on these data, new markers and the systems of markers predicting tumor dissemination were selected. Using methylation-specific PCR and a representative set of 54 ovarian cancer samples, we identified 10 microRNA genes (MIR-124a-2, MIR-127, MIR-125b-1, MIR-129-2, MIR-137, MIR-193a, MIR-203a, MIR-34b/c, MIR-130b, and MIR-1258) whose methylation is associated with tumor metastasis. The greatest association was established for 4 genes: MIR-137, MIR-193a, MIR-34b/c, and MIR-130b (p<0.01). ROC analysis revealed 3 most optimal marker systems including 4-5 miRNA genes and characterized by high sensitivity (82-94%) and specificity (76-86%) at AUC=0.89-0.92. Methylation of any three genes from these systems is sufficient to predict metastasis with the specified accuracy. Detection of the group of hypermethylated miRNA genes with predictive value for ovarian cancer metastasis is of great importance for personalized treatment of the patients.

About the authors

E. A. Filippova

Research Institute of General Pathology and Pathophysiology

Email: eleonora10_45@mail.ru
Russian Federation, Moscow

V. I. Loginov

Research Institute of General Pathology and Pathophysiology; Research Center for Medical Genetics

Email: eleonora10_45@mail.ru
Russian Federation, Moscow; Moscow

A. M. Burdennyi

Research Institute of General Pathology and Pathophysiology

Email: eleonora10_45@mail.ru
Russian Federation, Moscow

E. A. Braga

Research Institute of General Pathology and Pathophysiology; Research Center for Medical Genetics

Author for correspondence.
Email: eleonora10_45@mail.ru
Russian Federation, Moscow; Moscow

I. V. Pronina

Research Institute of General Pathology and Pathophysiology

Email: eleonora10_45@mail.ru
Russian Federation, Moscow

T. P. Kazubskaya

N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation

Email: eleonora10_45@mail.ru
Russian Federation, Moscow

D. N. Kushlinskii

N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation

Email: eleonora10_45@mail.ru
Russian Federation, Moscow

D. O. Utkin

N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation

Email: eleonora10_45@mail.ru
Russian Federation, Moscow

M. V. Fridman

N. I. Vavilov Institute of General Genetics, Russian Academy of Sciences

Email: eleonora10_45@mail.ru
Russian Federation, Moscow

D. S. Khodyrev

Federal Scientific and Clinical Center of Specialized Medical Care and Medical Technologies, Federal Medical-Biological Agency of the Russia

Email: eleonora10_45@mail.ru
Russian Federation, Moscow

N. E. Kushlinskii

N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation

Email: eleonora10_45@mail.ru
Russian Federation, Moscow


Copyright (c) 2019 Springer Science+Business Media, LLC, part of Springer Nature

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies